Top Markets
Coin of the day
Peak Bio, Inc. Peak Bio, Inc.

Peak Bio, Inc.

PKBO
Rang in Aktien #37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Aktienkurs
$0.07
Zuletzt synchronisiert: 2024-11-12
Marktkapitalisierung
$1.62M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Peak Bio, Inc. (PKBO)

Kategorie

Dividendenrendite-Verlauf für Peak Bio, Inc. (PKBO)
Dividendenrendite (TTM) von Peak Bio, Inc. (Aktienkürzel: PKBO) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Peak Bio, Inc. (PKBO) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber